Your browser doesn't support javascript.
loading
Feasibility of using stereotactic body radiation therapy for unresectable soft tissue tumors of the trunk.
Paik, Eun Kyung; Kim, Mi-Sook; Cho, Chul-Koo; Yoo, Hyung Jun; Jang, Won Il; Seo, Young-Seok; Jin, Sung-Ho; Jeon, Dae Geun; Lee, Dong Han.
Afiliação
  • Paik EK; Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
  • Kim MS; Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
  • Cho CK; Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
  • Yoo HJ; Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
  • Jang WI; Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
  • Seo YS; Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea.
  • Jin SH; Department of Surgery, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
  • Jeon DG; Department of Orthopedic Surgery, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
  • Lee DH; CyberKnife Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Oncotarget ; 9(45): 27851-27857, 2018 Jun 12.
Article em En | MEDLINE | ID: mdl-29963242
ABSTRACT

PURPOSE:

To evaluate the feasibility of stereotactic body radiation therapy (SBRT) for unresectable soft tissue tumors of the trunk. MATERIALS AND

METHODS:

Between January 2002 and December 2008, 23 patients with 36 lesions of soft tissue tumors, which were located in the trunk and not suitable for resection, underwent SBRT. Among the 36 lesions, 31 were malignant and 5 were benign. The median tumor volume was 24 cm3 (range, 2.6-213 cm3). SBRT doses ranged from 20 to 48 Gy in 1-5 fractions.

RESULTS:

With a median follow-up of 73 months, the overall survival (OS) and local control (LC) rates at 5 years were 39% and 52%, respectively. For malignant tumors, the OS and LC rates at 5 years were 28% and 47%, respectively. For benign tumors, the OS and LC rates at 5 years were 80% and 100%, respectively. There was no acute toxicity of grade ≥3. One case of grade 3 late skin toxicity was reported 10 months after SBRT.

CONCLUSION:

SBRT may be an effective and safe treatment modality for the local control of unresectable soft tissue tumors of the trunk including tumors of a benign nature.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article